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As part of a larger investigation of cancer in Uganda, we conducted a case–control study of conjunctival squamous cell
carcinoma in adults presenting at hospitals in Kampala. Participants were interviewed about social and lifestyle factors and had
blood tested for antibodies to HIV, KSHV and HPV-16, -18 and -45. The odds of each factor among 60 people with
conjunctival cancer was compared to that among 1214 controls with other cancer sites or types, using odds ratios, estimated
with unconditional logistic regression. Conjunctival cancer was associated with HIV infection (OR 10.1, 95% conﬁdence
intervals [CI] 5.2–19.4; P50.001), and was less common in those with a higher personal income (OR 0.4, 95% CI 0.3–1.2;
P50.001). The risk of conjunctival cancer increased with increasing time spent in cultivation and therefore in direct sunlight
(w
2 trend=3.9, P=0.05), but decreased with decreasing age at leaving home (w
2 trend=3.9, P=0.05), perhaps reﬂecting less
exposure to sunlight consequent to working in towns, although both results were of borderline statistical signiﬁcance. To
reduce confounding, sexual and reproductive variables were examined among HIV seropositive individuals only. Cases were
more likely than controls to report that they had given or received gifts for sex (OR 3.5, 95% CI 1.2–10.4; P=0.03), but this
may have been a chance ﬁnding as no other sexual or reproductive variable was associated with conjunctival cancer, including
the number of self-reported lifetime sexual partners (P=0.4). The seroprevalence of antibodies against HPV-18 and -45 was
too low to make reliable conclusions. The presence of anti-HPV-16 antibodies was not signiﬁcantly associated with squamous
cell carcinoma of the conjunctiva (OR 1.5, 95% CI 0.5–4.3; P=0.5) and nor were anti-KSHV antibodies (OR 0.9, 95% CI 0.4–
2.1; P=0.8). The 10-fold increased risk of conjunctival cancer in HIV infected individuals is similar to results from other studies.
The role of other oncogenic viral infections is unclear.
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Squamous cell carcinoma of the conjunctiva is thought to be an
extreme form of a spectrum of clinical conditions, collectively
known as ‘ocular surface squamous neoplasias’, which range in
severity from mild dysplasia, to carcinoma in situ and, ultimately,
to invasive carcinoma. Symptoms can range from none, to severe
pain and visual loss. Lesions generally arise on exposed areas of
the eye, particularly on the nasal side, and treatment involves local
excision, or in more severe cases, orbital clearance. Metastases are
rare and the prognosis is usually favourable.
Although relatively rare everywhere, conjunctival carcinoma is
more frequent in parts of sub-Saharan Africa. Uganda offers a good
setting in which to investigate the epidemiology of squamous cell
carcinoma of the conjunctiva, because the tumour was relatively
frequent there, even before the onset of the HIV epidemic
(Templeton, 1973; Wabinga et al, 2000). In this report, we examine
the association of conjunctival tumours with over 50 possible risk
factors, including evidence of infection with HIV-1, HPV-16, -18
and -45 and Kaposi’s sarcoma-associated herpesvirus (KSHV;
human herpesvirus type 8 [HHV-8]), using data from a case-
control study of cancer in adults (Ziegler et al, 1997; Newton et
al, 2001).
MATERIALS AND METHODS
Study subjects
The subjects included in these analyses were selected from a large
cross-sectional study of risk factors for cancer in Uganda, which
included, in total, 2091 individuals with malignancies other than
Kaposi’s sarcoma. Between August 1994 and February 1998, any
adults (aged 15 years and over) with a provisional new diagnosis
of incident cancer were eligible for recruitment into the study from
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www.bjcancer.comall the wards and out-patient clinics of the four main hospitals in
Kampala, Uganda: Mulago (including the Uganda Cancer Institute),
Nsambya, Mengo and Rubaga. Further details of the methods can be
found elsewhere (Ziegler et al, 1997; Newton et al, 2001). The
subjects included in this report are restricted to 60 cases of conjunc-
tival cancer and 1214 controls. Thirty-two people with eye cancers
that were not speciﬁcally diagnosed clinically as being squamous cell
carcinomas, or had a pathological diagnosis of malignancy of uncer-
tain morphology were excluded. The controls comprised people
with other incident cancers, excluding those with cancer sites or
types that are known to be associated with infection with HIV,
HPV or KSHV, or exposure to solar ultraviolet radiation – that
is, Kaposi’s sarcoma, non-Hodgkin’s lymphoma, Hodgkin’s disease,
cancers of the uterine cervix, anus and penis, and skin cancers
(IARC, 1992, 1995; Beral and Newton, 1998). The control group
included men and women with cancers of the oral cavity (57), oeso-
phagus (150), stomach (74), liver (103), breast (178), ovary (67),
prostate (56), and other cancer sites or types (405). In addition,
124 patients with a provisional diagnosis of cancer, but who subse-
quently turned out to have benign tumours, were also included in
the control group.
Recruitment and questionnaire
Interviewers (who were also trained HIV counsellors) approached
ward or clinic staff to gain permission to interview potential
recruits. If permission was granted, the patient was approached
by one of four interviewers and invited to participate in the study.
A HIV test was requested and appropriate counselling was given.
Patients who had been HIV tested within a month of recruitment
and had a medical certiﬁcate indicating the test result, were not re-
tested. The patient was interviewed about social and demographic
factors, and sexual and reproductive history. Where possible, the
patient was interviewed by a counsellor of the same sex, and in
their native language. Blood was drawn, primarily for the HIV test,
but also for storage of serum and leukocytes. Interviewers reported
the HIV test results back to the patient, together with post-test
counselling. The study was approved by the Committee on Human
Research (VA Medical Centre and University of California, San
Francisco, CA, USA) and by the Uganda National Council for
Science and Technology.
Laboratory diagnoses
Histology Diagnoses of cancer were established by histology or
other laboratory investigation, where possible. Diagnoses made
on clinical grounds alone, were reviewed by the investigators (C
A-A, JZ, EM and SM). Among the cases, 36 (60%) underwent
histological review (all were invasive tumours) and the remainder
were diagnosed clinically. Among controls, 63% of tumour diag-
noses were veriﬁed by laboratory investigation (histology,
cytology, blood chemistry or ultrasound examination).
HIV-1 HIV-1 serostatus was determined using a single ELISA,
the Cambridge Bioscience Recombigen enzyme linked immunosor-
bent assay (Cambridge, MA, USA). Periodic laboratory quality
control assays using blinded standards from the United States
Centers for Disease Control (Atlanta, GA, USA) revealed test sensi-
tivity and speciﬁcity of 99%. In the initial months of the study,
40–50% of adults declined to have venepuncture, mostly because
they were too ill. Therefore, a GACELISA saliva test for HIV was
introduced as an option (with sensitivity and speciﬁcity similar
to the blood test), and the refusal rate dropped to 10%. In total,
HIV test results were available on 57 cases and 826 controls.
However, for one case and seven controls the result was indetermi-
nate. Any remaining aliquots of sera were stored at 7808C and
were later shipped on dry ice to the Laboratoire de Virologie Mole ￿-
culaire in Tours, France, for HPV testing and to University College
London, UK, for KSHV testing.
HPV-16, -18 and -45 All assays were performed by a single
investigator (LB), who was unaware of each patient’s personal char-
acteristics, and diagnosis. HPV VLPs were produced in Sf21 insect
cells using recombinant baculoviruses encoding the L1 gene of
HPV-16, -18, and -45, according to previously described procedures
(Touze ￿ et al; 1998; Combita et al, 2002a,b). These subtypes were
chosen because they are known to be prevalent in tumour speci-
mens from women with cancer of the uterine cervix in Uganda
(Bosch et al, 1995). Brieﬂy, the HPV L1 genes were ﬁrst ampliﬁed
from an HPV DNA-positive biopsy using primers containing BglII
sites. The ampliﬁed product was then inserted into pFastBacI to
generate HPV L1 VLPs. VLPs were produced according to a proce-
dure used for HPV-16 VLPs (Touze ￿ et al, 1998; El Mehdaoui et al,
2000). Sf21 cells, maintained in Grace’s insect medium supplemen-
ted with 10% foetal calf serum (FCS) were infected with the
different recombinant baculoviruses at a m.o.i. of 10 and were incu-
bated for 72 h at 278C. Cells were harvested by centrifugation, re-
suspended in PBS containing 0.5% NP40 and allowed to stand at
room temperature for 30 min. Cell lysates were then centrifuged
at 140006g for 15 min at 48C. The nuclear fractions were further
re-suspended in ice cold PBS and sonicated by three 15 s bursts at
60% maximal power (Vibra Cell, Bioblock Scientiﬁc, Strasbourg,
France). Fractions were then loaded on the top of a preformed CsCl
gradient and centrifuged at equilibrium in a Beckman SW28 rotor
(20 h, 27000 r.p.m., 48C). Gradient fractions were analysed for
density by refractometry and were tested for the presence of L1
protein by ELISA. Immunoreactive fractions were ﬁnally pooled
and pelleted by ultracentrifugation in a Beckman SW 28 rotor
(3 h, 28000 r.p.m., 48C). VLPs were resuspended in PBS (pH 7.4)
and protein content was evaluated using the microBCA kit (Pierce,
Touzart et Matignon, France). Each preparation was tested for the
presence of VLPs by electron microscopy. For this purpose, VLP
preparations were applied to 400-mesh carbon-coated grids, nega-
tively stained with 1.5% uranyl acetate and then examined at a
nominal magniﬁcation of 50000 with a Jeol 1010 electron micro-
scope. VLPs were then diluted in PBS and used in the following
ELISA tests (Touze ￿ et al, 1998; Combita et al, 2002a).
Flat-bottomed wells of 96-well microplates (Maxisorp, Nunc, Life
Technologies, Eragny, France) were coated overnight at 48C with
200–400 ng of VLPs (test well) or 200 ng of BSA (control well) in
PBS, pH 7.4. Each serum sample was tested twice against each of
the seven VLP types and BSA at the same time on the same plate.
After washing with PBS, 0.1% Tween 20 and 200 ml of PBS contain-
ing 1% newborn bovine serum (NBS, Sigma, St Quentin Favallier,
France) were added (2 h at 378C). The blocking solution was
replaced by 100 ml of sera diluted 1:20 in 5xPBS-10% NBS and
2% Tween 20, and plates were incubated at 458C for 60 min. After
four washes, bound antibodies were detected with a goat anti-human
IgG immunoglobulin (diluted 1:5000) conjugated to horseradish
peroxidase (Sigma). Following incubation at 458C for 1 h and four
washes, 100 ml of a substrate solution containing ortho-phenylene-
diamine and H2O2 was added. After 30 min incubation, the
reaction was stopped by addition of 100 mlo f4 NH 2SO4, and optical
densities (OD) were read at 492 nm with an automated plate reader
(BioRad, model 550). For each serum sample the background reac-
tivity found in the BSA coated wells was subtracted from the OD
found in each of the HPV–VLP coated wells. Negative values were
adjusted to zero. The cut-off values for positivity to HPV-16, -18
and -45 were set up at 0.2 (OD test well minus OD control well)
and those with a value of 0.4 or greater were considered to have a
high titre of anti-HPV antibodies. In total, 457 samples were available
for testing for antibodies against HPV-16 (39 cases and 418 controls).
In addition, there were sufﬁcient sera for 453 of those to be tested for
antibodies against HPV-18 and -45 (39 cases and 414 controls).
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who was unaware of each patient’s personal characteristics, and diag-
nosis. A body-cavity-related B-cell lymphoma cell, BCP-1, which is
positive for KSHV and negative for Epstein–Barr virus, was used
for an indirect immunoﬂuorescence assay to detect IgG antibodies
against KSHV antigen (Gao et al, 1996; Boshoff et al, 1998). Latently
infected BCP-1 cells were ﬁxed in 4% paraformaldehyde and were
made permeable with 0.2% Triton X-100. Cells were re-suspended
in phosphate-buffered saline and ﬁxed on glass slides. The samples
were diluted 1:100 in phosphate-buffered saline with 3% foetal calf
serum. The diluted serum was added to ﬁxed BCP-1 cells and incu-
bated at 228C for 45 min. After the slides were washed in
phosphate-buffered saline with 3% foetal calf serum, rabbit antihu-
man IgG labelled with ﬂuorescein isothiocyanate (Dako, High
Wycombe, UK), diluted 1:40 in phosphate-buffered saline with
3% foetal calf serum, was added and the slides were incubated at
228C for 20 min. The slides were then washed in phosphate-buffered
saline without foetal calf serum and screened by ultraviolet micro-
scopy for the nuclear stippling pattern characteristic of antibodies
against the latent nuclear antigen of KSHV encoded by orf73 (Gao
et al, 1996). In total, 416 samples were available for testing for anti-
bodies against KSHV (32 cases and 384 controls).
Statistical methods
Data were computerised by trained clerks using EPI-INFO-5 soft-
ware, and statistical analyses were conducted using STATA 7.0
(Dean et al, 1990; STATA Corp, 2001). The odds ratio (OR) for each
variable in cases versus controls, was estimated with unconditional
logistic regression. All odds ratios were adjusted for age (15–24,
25–34, 35–44 and 45+), sex, HIV-1 sero-status and personal income
(less than 20000 Uganda Shillings per year or 20000+ Shillings).
Additional adjustment was made for region of residence (Kampala
or elsewhere), because most cases had been identiﬁed from out-
patient clinics, which tend to draw patients from the local area,
whereas controls had been hospital in-patients, who are from a wider
area (Ziegler et al, 1997). These factors were selected a priori, with the
exception of personal income, which was included following preli-
minary analyses. HIV infection is sexually transmitted and is
strongly associated with many of the sexual and reproductive vari-
ables studied (data not shown). In order to avoid confounding,
these factors were examined among HIV seropositive individuals
only (there were too few HIV seronegative people to justify analysis).
All P values are two-sided. Note that numbers of cases and controls in
the tables do not always add to the total, because of missing values.
RESULTS
Among those with conjunctival cancer, 43% (26 out of 60) were men
and 57% (34 out of 60) were women. The proportion of all cancers
comprising conjunctival carcinoma declined from 9% in those aged
15–24 years to 2% in those over the age of 45 years. Seven per cent
of cases and 5% of controls were born in Kampala, the remainder
being born outside the capital city (P=0.7) and, 41% of cases and
23% of controls reported their current residence as being in Kampala
(Table 1; P=0.13). The seroprevalence of anti-HIV-1 antibodies was
70% among cases and 15% among controls (Odds ratio [OR] 10.1,
95% conﬁdence intervals [CI] 5.2–19.4; P50.001). The risk of
conjunctival carcinoma was signiﬁcantly lower among those with a
high personal income (OR 0.4, 95% CI 0.2–0.7; P50.001). For
those who left home at ages 21+ years (including those who never
left), 15–20 years and 1–14 years, the odds ratio was 1.0 (reference
group), 0.7 (0.4–1.5) and 0.4 (0.2–1.0) respectively (Ptrend=0.05).
Study participants were asked how long each week they spent culti-
vating, 0–9 h, 10–19 h or 20+ h. The risk of conjunctival
carcinoma increased signiﬁcantly with increasing time spent cultivat-
ing (ORs 1.0, 1.9 and 2.4 respectively; Ptrend=0.03).
Table 2 shows the results for anti-HPV and KSHV antibodies.
The seroprevalence of anti-HPV antibodies in controls was 10%
for HPV-16 (43 out of 418), 4% (16 out of 414) for HPV-18
and 6% (24 out of 414) for HPV-45. The corresponding results
for those with conjunctival cancer were 21% (eight out of 39),
10% (four out of 39) and 5% (two out of 39) respectively.
However, after adjustment for age, sex, address, HIV status and
personal income, there were no statistically signiﬁcant associations
between the presence of anti-HPV-16, -18 and -45 antibodies and
the risk of conjunctival carcinoma. Results for each HPV subtype
were also calculated according to a measure of the antibody titre:
the optical densities at each level correspond to less than 0.2 for
negative, 0.270.39 for medium titre and 0.4 or above for high
titre. The numbers of cases and controls with anti-HPV antibodies
to subtypes -18 and -45 were too few to yield any signiﬁcant
results. The results for anti-HPV-16 antibodies at each measure
of titre were 1.0 (HPV-16 antibody negative, based on 31 cases
and 375 controls), 0.7 (0.2–2.9; medium titre, based on four cases
and 31 controls) and 6.3 (1.2–33.4; high titre, based on four cases
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Table 1 Distribution of region of birth, region of residence, tribe, nation-
ality, HIV-1 sero-status, income, age left home and time spent cultivating
among cases with conjunctival carcinoma and controls with other can-
cers, in Uganda
Number of Odds ratio and 95%
cases/controls conﬁdence intervals
a
Region of birth
Kampala 4/54 1.0
Rest of Uganda 59/982 1.2
w
2 heterogeneity (1df)=0.1; P=0.7
Region of residence
Kampala 25/272 1.0
Rest of Uganda 35/922 0.6
w
2 heterogeneity (1df)=2.3; P=0.1
Tribe
Baganda 27/631 1.0
Other 33/560 1.4
w
2 heterogeneity (1df)=1.3; P=0.3
Nationality
Ugandan 56/1132 1.0
Other 4/59 1.4
w
2 heterogeneity (1df)=0.3; P=0.6
HIV-1 sero-status
Negative 17/700 1.0
Positive 39/119 10.1
w
2 heterogeneity (1df)=52.9; P50.001
Personal income (SH)
520,000 30/408 1.0
20,000+ 29/552 0.4
w
2 heterogeneity (1df)=9.5; P50.001
Household income (SH)
530,000 33/485 1.0
30,000+ 22/419 0.6
w
2 heterogeneity (1df)=1.9; P=0.2
Age left home (years)
21+ (or never left) 22/330 1.0
15–20 26/375 0.7
1–14 11/292 0.4
w
2 trend (1df)=3.9; P=0.05
Time spent cultivating
(Hours per week)
0–9 9/241 1.0
10–19 23/401 1.9
20+ 26/348 2.4
w
2 trend (1df)=3.9; P=0.05
aOdds ratios adjusted for age group, sex, current region of residence, HIV-1 status
and personal income. df=degrees of freedom.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(3), 301–308and 12 controls; Ptrend=0.2). Only 15 people had anti-HPV antibo-
dies to more than one tested HPV subtype (two cases and 13
controls) and there was no signiﬁcant excess risk of the tumour
in these individuals, as compared to those who were considered
to be negative for all three subtypes (OR 0.6, 95% CI 0.1–4.3).
In relation to Kaposi’s sarcoma-associated herpesvirus, the seropre-
valence of anti-KSHV antibodies was 47% (15 out of 32) among
cases and 49% (188 out of 384) among controls (OR 0.9, 95%
CI 0.4–2.1; P=0.8).
Further results are provided in Appendices 1–4. Results for
other social and demographic factors, none of which was associated
with an increased risk of conjunctival carcinoma, are shown in
Appendix 1. Factors, other than income, that might characterise
wealth and social status in Uganda, such as ownership of livestock
and travel away from home, are shown in Appendix 2. None of
these variables were associated with conjunctival carcinoma.
Appendix 3 shows results for other possible exposures. Those
who reported having had a blood transfusion in the past were less
likely to be cases (OR 0.4, 95% CI 0.2–0.9; P=0.02). Results for
sexual and reproductive variables among HIV seropositive people
only, are shown in Appendix 4. A self reported history of having
either given or received gifts in exchange for sex was associated
with an increased risk of the tumour (OR 3.5, 95% CI 1.2–10.4;
P=0.03), although this may have been a chance ﬁnding as there
was no statistically signiﬁcant association with any other sexual
or reproductive variable, including the reported number of lifetime
sexual partners (P=0.4).
DISCUSSION
Here, we report an investigation of the epidemiology and aetiology
of conjunctival squamous cell carcinoma, examining over 50 risk
factors for the tumour. Conjunctival cancer affects relatively young
individuals of both sexes and is strongly associated with HIV infec-
tion and poverty. In addition, the risk of the disease decreases with
decreasing age at which an individual leaves home and with
increasing time spent cultivating, although both results are of
borderline statistical signiﬁcance. Furthermore, signiﬁcance tests
were conducted on over 50 risk factors, greatly increasing the like-
lihood of signiﬁcant results arising by chance alone. The role of
HPV-16, -18 and -45 requires further evaluation, but KSHV does
not appear to be associated with conjunctival carcinoma.
The study reported here is subject to the potential problems of
incomplete diagnostic veriﬁcation and HIV testing. Laboratory veri-
ﬁcation of cancer diagnosis (for example, by histology, cytology or
blood chemistry) was available on 60% of cases (all of which were
invasive tumours) and 63% of controls. Typical of studies in devel-
oping countries where laboratory services are limited, this
proportion compares favourably with other cancer series reported
from Africa (Bassett et al, 1995; Newton et al, 1996a; Wabinga et
al, 2000). Another potentially important source of bias is the high
proportion of adults who were not tested for HIV in the early
stages of the study. However, the age and sex-speciﬁc seropreva-
lence rates of HIV infection among those tested is broadly similar
to that found in studies of HIV seroprevalence in Uganda (STD/
AIDS Control Programme, Uganda, 1997). Also, the introduction
of a saliva test resulted in a dramatic reduction in refusals, but little
change in HIV seroprevalence rates, suggesting that patients who
were refusing to have a HIV test were unwilling to have blood
taken, rather than unwilling to learn their HIV serostatus. The asso-
ciation of conjunctival cancer with HIV infection has been reported
in a general paper on HIV and cancer among residents of Kampala,
and the odds ratio was the same as that from the current study of
all patients who were seen at hospitals in Kampala (Newton et al,
2001). A proportion of individuals in the study were also tested
for antibodies to three HPV subtypes and to KSHV infection. This
additional testing occurred in all those for whom enough stored
sera were available and (as people are unaware of their own status
with respect to infection), is therefore an unbiased sample.
Another potential source of bias arises from the fact that most
(but not all) cases had been identiﬁed from out-patient clinics,
which tend to draw patients from the local area, whereas controls
had been hospital in-patients, who are from a wider area. Despite
adjusting for region of residence in the analyses, the possible
impact of this on the results, is difﬁcult to assess.
Case reports of squamous cell carcinoma of the conjunctiva in
human immunodeﬁciency virus (HIV) infected men in the USA
and France, coupled with a marked increase in the numbers of
tumours being seen by ophthalmologists in at least two African
centres (which mirrored the increases seen for Kaposi’s sarcoma),
led to the suggestion of an association with HIV (Winward and
Curtin, 1989; Ateenyi-Agaba, 1995; Kestelyn et al, 1990; Kim et al,
1990; Denis et al, 1994). Among those with HIV, the lesions often
affect young adults, in a fashion reminiscent of Kaposi’s sarcoma in
HIV-seropositive people (Ateenyi-Agaba, 1995; Kestelyn et al, 1990;
Waddell et al, 1996). This study, together with others from Africa
and the USA indicate about a 10-fold increased risk of the tumour
in HIV infected, compared to HIV uninfected individuals (Ateenyi-
Agaba, 1995; Kestelyn et al, 1990; Goedert and Cote ￿, 1995; Newton
et al, 1995, 2001; Waddell et al, 1996). Indeed, the spread of HIV
in Uganda probably accounts for much of the approximately eight-
fold increase in incidence of conjunctival carcinoma observed there
since the 1960s (Wabinga et al, 2000). Using standard equations for
case–control studies, the population attributable fraction is about
60%: almost two-thirds of cases would not occur in the absence of
HIV infection (dos Santos Silva, 1998). However, the frequency of
conjunctival carcinoma is not such that it is yet a particularly
common manifestation of HIV disease (Piot et al, 1992).
The mechanism whereby HIV infection increases the risk of
conjunctival cancer is not clear. There is no evidence that it is
directly oncogenic and the impact on cancer risk is most likely
to be mediated via immunosuppression, as is the case for other
HIV-associated cancers (Beral and Newton, 1998; Newton et al,
1999). It is not known if the risk of conjunctival squamous cell
carcinoma is increased in other immunosuppressed groups, such
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Table 2 Comparison of human papillomavirus antibodies (HPV types 16,
18 and 45) and Kaposi’s sarcoma-associated herpesvirus (KSHV) antibodies
between those with conjunctival cancer and those without
Number of Odds ratio and 95%
cases/controls conﬁdence intervals
a
HPV-16
Negative 31/375 1.0
Positive 8/43 1.5 (0.5–4.3)
w
2 heterogeneity (1df)=0.5; P=0.5
HPV-18
Negative 35/398 1.0
Positive 4/16 2.3 (0.5–9.6)
w
2 heterogeneity (1df)=1.2; P=0.3
HPV-45
Negative 37/390 1.0
Positive 2/24 0.4 (0.1–2.1)
w
2 heterogeneity (1df)=1.5; P=0.2
HPV-16, -18 or -45
All negative 28/345 1.0
Any positive 11/69 1.3 (0.5–3.2)
w
2 heterogeneity (1df)=0.4; P=0.6
KSHV
Negative 17/196 1.0
Positive 15/188 0.9 (0.4–2.1)
w
2 heterogeneity (1df)=0.1; P=0.8
aAdjusted for age, sex, address, personal income and HIV-1 sero-status.
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the world where tissue transplantation occurs. However, there is a
case report of a conjunctival cancer in a patient with malignant
lymphoma on immunosuppressive chemotherapy (Kushner and
Mushen, 1975). In general, HIV infection is thought to increase
cancer risk by facilitating the action of other oncogenic viruses,
such as KSHV, the principal cause of Kaposi’s sarcoma. In relation
to conjunctival cancer however, we found no evidence in these data
of an association with KSHV.
Several types of squamous carcinoma are associated with human
papillomavirus (HPV) infection, most notably cancer of the uterine
cervix, induced primarily by HPV-16, -18 and others. Squamous
carcinoma of the skin has also been associated with HPV-5 and
-8 in immunosuppressed individuals (IARC, 1995). Evidence for
an association between human papillomavirus and squamous cell
carcinoma of the conjunctiva is conﬂicting, although bovine papil-
lomaviruses are thought to cause conjunctival carcinomas in cattle
(IARC, 1995). The presence of human papillomavirus DNA (HPV;
predominantly types 16, but also other types) in human ocular
surface squamous neoplasias, including invasive carcinomas, has
been reported in some studies, but not others (reviewed by
Newton, 1996). This is the ﬁrst study to look for an association
between anti-HPV antibodies (types -16, -8 and -45) and the risk
of conjunctival carcinoma. The seroprevalence of antibodies against
HPV-18 and -45 was too low to make reliable conclusions. Results
for anti-HPV-16 antibodies were suggestive of an association
among individuals with high titres, but the data presented here
are too few to draw valid conclusions and studies of larger
numbers of cases are required.
The HPV assays used in this study are based on the expression
of L1 major capsid proteins of HPV-16, -18 and -45 in insect cells
by using recombinant baculoviruses (Touze ￿ et al, 1998). The result-
ing virus-like particles (VLPs), which appear similar to empty
virions, can be used in serological studies to test for type speciﬁc
immunological responses to viral capsid proteins, although there
is evidence that a particular assay may cross react with related
HPV subtypes (Combita et al, 2002b). Presence of anti-VLP anti-
bodies is an indicator of past and current infection (Kirnbauer et
al, 1994; Le Cann et al, 1995; Wideroff et al, 1995; Dillner et al,
1996). The utility of such assays has been demonstrated in previous
studies of anti-HPV-16 antibodies in relation to the risk of cancer
of the uterine cervix (Lehtinen et al, 1996; Dillner et al, 1997; Shah
et al, 1997; Vonka et al, 1999; Hisada et al, 2001). Results from this
study on the relationship between anti-HPV-16 antibodies and the
risk of cancer of the uterine cervix are broadly comparable to those
reported before and will be the subject of a separate report.
Although relatively rare everywhere, conjunctival carcinoma is
more frequent in sub-Saharan Africa and other tropical areas than
in temperate countries, leading to the hypothesis that it may be
associated with exposure to solar ultraviolet radiation (Templeton,
1973; Clear, 1979). Geographical studies support this premise, in
that the incidence of squamous carcinoma of the eye increases as
exposure to ambient solar ultraviolet radiation increases. Levels
of solar radiation are higher towards the equator and the incidence
of conjunctival cancer increases by about 50% for each 108 decline
in latitude (Newton et al, 1996b; Sun et al, 1997). In addition, a
single case–control study reported that the risk of ocular surface
epithelial dysplasias is greatest in those reporting a past history
of skin cancer, which is known to be caused by exposure to solar
ultraviolet radiation (Lee et al, 1994). Time spent cultivating may
indicate the time an individual spends in direct sunlight, and so
the increasing risk with increasing time cultivating may reﬂect
exposure to ultraviolet radiation. This variable may also reﬂect
exposure to dust or dirt, and it has been hypothesised that ocular
trauma could facilitate development of the tumour (Templeton,
1973; Margo and Groden, 1986). The lower risk among people
who leave home at an earlier age may reﬂect migration to towns
for work, where exposure to solar ultraviolet radiation could be
less. The extent to which the higher risk among those of low
income is measuring the previously mentioned exposures is not
clear. The fact that cases are less likely than controls to have had
a blood transfusion is probably an artefact of the control selection.
Cases were generally seen as out-patients, whereas controls with
other cancers were generally hospital in-patients. The latter may
therefore be more likely to have had a transfusion as part of their
medical care.
In summary, the current study gives independent support for
the strong epidemiological evidence that solar ultraviolet radiation
is an important cause of squamous cell carcinoma of the conjunc-
tiva. Another established risk factor is HIV infection, although the
mechanism whereby it increases the risk of conjunctival cancer is
not clear. We ﬁnd little evidence supporting the possible role of
sexually transmitted forms of HPV in the aetiology of conjunctival
cancer, but larger studies are required.
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Appendix 1 Comparison of social and demographic factors between
people with and without conjunctival cancer
Number of Odds ratio and 95%
cases/controls conﬁdence intervals
a
Years at current address
510 27/220 1.0
10+ 33/778 0.8
w
2 heterogeneity (1df)=0.8; P=0.4
Settlement type
1–99 houses 29/704 1.0
100+ houses 31/287 1.5
w
2 heterogeneity (1df)=1.7; P=0.2
Travel time to market
530 mins 40/400 1.0
30+ mins 14/456 0.6
w
2 heterogeneity (1df)=2.0; P=0.2
Age left school
No school 7/270 1.0
515 years 25/289 1.4
16–19 years 20/262 1.2
20+ years 8/163 0.8
w
2 trend (1df)=0.4; P=0.5
Education level
No school 7/273 1.0
Primary 19/272 1.5
Secondary/tertiary 34/450 1.1
w
2 trend (1df)=0.7; P=0.4
Religion
Christian 55/882 1.0
Muslim 5/125 0.8
w
2 heterogeneity (1df)=0.2; P=0.7
Occupation
Cultivator 14/588 1.0
Other 46/549 1.7
w
2 heterogeneity (1df)=1.8; P=0.2
Number in house
55 25/383 1.0
5+ 35/621 1.2
w
2 heterogeneity (1df)=0.3; P=0.6
Number of siblings
55 32/567 1.0
5+ 28/438 0.8
w
2 heterogeneity (1df)=0.7; P=0.4
Birth order
1–2 25/467 1.0
3+ 35/538 0.9
w
2 heterogeneity (1df)=0.1; P=0.7
Number sharing toilet
56 19/358 1.0
6+ 40/610 1.1
w
2 heterogeneity (1df)=0.0; P=0.9
aAdjusted for age group, sex, address, personal income and HIV-1 sero-status;
df=degrees of freedom.
Appendix 2 Comparison of factors characterising wealth between
those with and without conjunctival cancer
Number of Odds ratio and 95%
cases/controls conﬁdence intervals
a
Number of rooms in house
1–2 31/306 1.0
3+ 29/696 0.8
w
2 heterogeneity (1df)=0.4; P=0.5
Electricity
No 38/770 1.0
Yes 21/228 1.0
w
2 heterogeneity (1df)=0.0; P=1.0
Own radio
No 11/205 1.0
Yes 49/794 1.0
w
2 heterogeneity (1df)=0.0; P=0.9
Own motorcar
No 56/890 1.0
Yes 4/109 0.5
w
2 heterogeneity (1df)=1.8; P=0.2
Own bicycle
No 35/523 1.0
Yes 25/478 1.0
w
2 heterogeneity (1df)=0.0; P=0.9
Own cows
None 50/736 1.0
1+ 9/259 0.7
w
2 heterogeneity (1df)=0.7; P=0.4
Own pigs and goats
None 46/677 1.0
1+ 14/319 1.2
w
2 heterogeneity (1df)=0.3; P=0.6
Own chickens
None 38/542 1.0
1+ 22/431 1.1
w
2 heterogeneity (1df)=0.1; P=0.8
Travel away from home 4
7 nights per year
No 53/877 1.0
Yes 7/105 1.3
w
2 heterogeneity (1df)=0.2; P=0.7
aAdjusted for age group, sex, address, personal income and HIV-1 sero-status;
df=degrees of freedom.
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Appendix 4 Comparison of sexual and reproductive variables between
those with conjunctival cancer and those without, among HIV seropositive
individuals only
Number of Odds ratio and 95%
cases/controls conﬁdence intervals
a
Marital status
Single 1/10 1.0
Monogomous married 22/43 8.2
Polygamous married 9/22 9.8
Widower 4/26 3.3
Separated 3/10 4.2
w
2 heterogeneity (1df)=6.6; P=0.16
Age ﬁrst sex
518 years 26/65 1.0
18+ years 13/46 0.7
w
2 heterogeneity (1df)=0.8; P=0.4
Number of children
0–2 13/23 1.0
3–4 9/25 0.7
5–6 9/20 1.0
7+ 5/30 0.5
w
2 trend (1df)=0.4; P=0.5
Children with different
mothers or fathers
No 13/40 1.0
Yes 21/53 1.4
w
2 heterogeneity (1df)=0.5; P=0.5
No. sexual partners
1–4 13/50 1.0
5–7 10/17 2.7
8+ 16/40 1.8
w
2 trend (1df)=0.8; P=0.4
History sexual discharge
No 13/48 1.0
Yes 26/64 1.9
w
2 heterogeneity (1df)=2.1; P=0.2
Gifts for sex
Never 29/101 1.0
Ever 10/11 3.5
w
2 heterogeneity (1df)=5.0; P=0.03
Use condoms
Never 28/83 1.0
Ever 11/28 0.7
w
2 heterogeneity (1df)=0.5; P=0.5
Circumcised (men)
No 17/34 1.0
Yes 0/7 0.0
w
2 heterogeneity (1df)=1.3; P=0.3
Labial elongation (women)
No 5/17 1.0
Yes 16/51 0.9
w
2 heterogeneity (1df)=0.1; P=0.8
aAdjusted for age, sex, address and personal income.
Appendix 3 Comparison of other exposures between those with and
without conjunctival cancer
Number of Odds ratio and 95%
cases/controls conﬁdence intervals
a
Use of shoes
Never/rarely 26/619 1.0
Often/always 33/372 1.5
w
2 heterogeneity (1df)=1.5; P=0.2
Age ﬁrst use shoes (years)
515 36/423 1.0
15+ 23/532 1.1
w
2 heterogeneity (1df)=0.1; P=0.7
Soil colour
Black 36/549 1.0
Other 16/343 1.0
w
2 heterogeneity (1df)=0.0; P=0.9
Time spent in water
(hours per week)
51 hour 47/728 1.0
1+ hours 12/272 0.6
w
2 heterogeneity (1df)=2.9; P=0.1
Tobacco use
Never smoker 46/762 1.0
Ex-smoker 7/146 0.9
Current smoker 7/91 1.1
w
2 heterogeneity (1df)=0.0; P=1.0
Use of snuff
No 58/977 1.0
Yes 2/16 2.0
w
2 heterogeneity (1df)=0.6; P=0.4
Drink home-brewed alcohol
No 36/533 1.0
About once/week 6/155 0.4
2–4/week 8/131 1.0
Most days 9/178 0.9
w
2 heterogeneity (1df)=3.3; P=0.3
Blood transfusion
No 53/184 1.0
Yes 7/183 0.4
w
2 heterogeneity (1df)=5.6; P=0.02
Injection from traditional
healer
No 39/596 1.0
Yes 21/374 1.0
w
2 heterogeneity (1df)=0.0; P=0.9
aOdds ratios adjusted for age, sex, address, personal income and HIV-1 sero-status.
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